Document Classification

Section Type: RESULTS

Text: In the overall study population, transdermal sumatriptan was significantly superior to placebo at 1 hour post-activation for pain relief (29 % vs 19 %, respectively ; P <. 0135) and freedom from nausea (71 % vs 58 %, respectively ; P <. 05) and at 2 hours post-activation for freedom from pain (18 % vs 9 %, respectively ; P <. 009), pain relief (53 % vs 29 %, respectively ; P <. 0001), freedom from nausea (84 % vs 63 % respectively ; P <. 001), freedom from photophobia (51 % vs 36 %, respectively ; P <. 0028), freedom from phonophobia (55 % vs 39 %, respectively ; P <. 0002) ; and freedom from migraine (16 % vs 8 %, respectively ; P <. 0135).